Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
Key facts
- Where
- Helsingborg, Karlstad, Orebro és Umea, SvédországSee the 4 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Svédország
- Region Skane Helsingborg HospitalHelsingborg, SvédországToborzás még nem indult
- Region VaermlandKarlstad, SvédországToborzás még nem indult
- Region Oerebro LaenOrebro, SvédországToborzás még nem indult
- Region VaesterbottenUmea, SvédországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Oerebro Laen
- Trial code
- EU 2026-525324-26-00
- Record updated
- 2026. június 5.
- Original description
To investigate the long-term outcomes and safety from repeated adjuvant treatment with the immunomodulatory drug rituximab in patients with schizophrenia or schizoaffective disorder.Read full original descriptionShow less
To investigate the long-term outcomes and safety from repeated adjuvant treatment with the immunomodulatory drug rituximab in patients with schizophrenia or schizoaffective disorder.
Inclusion: Have participated in the RCT-Rits trial; Signed informed consent; Duration of illness exceeding 2 years; Meets DSM-5 diagnostic criteria for schizophrenia or schizoaffective disorder at Baseline in RCT-Rits; Women (WOCBP) must be willing to use contraceptives or abstain for the duration of the study until one year after last rituximab treatment; Subjects should be assessed by the investigator to be clear and oriented when giving informed consent.
Exclusion: Malignancy, currently or within three years prior to inclusion; Treatments with monoclonal antibodies (other than rituximab), other immunomodulation treatments, or cytostatics within one year prior to inclusion; Any other physical condition that, in the judgement of the investigator, would make the subject unsuitable for participation in the trial; Clinically relevant ongoing infection; Chronic infections; Positive screening test for hepatitis B, C, HIV, or tuberculosis at Baseline in RCT-Rits; Severe heart disease; Pregnancy or breastfeeding; Hypogammaglobulinemia or neutropenia; Weight below 40 kg; Unable to make an informed decision to consent.